SUMMARY

trastuzumab deruxtecan

ENHERTU 100 mg**powder for concentrate for solution for infusion****New indication****Original French opinion adopted by the Transparency Committee on
24 May 2023****The legally binding text is the original French opinion version****Transparency Committee's conclusions****Clinical Benefit**

- ➔ Unresectable or metastatic breast cancer is a serious, life-threatening disease.
- ➔ The proprietary medicinal product ENHERTU (trastuzumab deruxtecan) is a curative medicinal product.
- ➔ The efficacy/adverse effects ratio is high due to:
- demonstration of the statistically and clinically significant superiority of trastuzumab deruxtecan versus the investigator's choice of chemotherapy on progression-free survival and overall survival,
- the acceptable safety profile.
- ➔ This is a treatment to be administered as monotherapy in adult patients with unresectable or metastatic HER2-low (IHC 1+ or IHC 2+/ISH-) breast cancer who have received prior chemotherapy in the metastatic setting or developed disease recurrence during or within six months of completing adjuvant chemotherapy.

➔ Public health benefit

Considering:

- the seriousness of the disease and its incidence;
- the partially met medical need;
- the partial response to the identified need given:
- a demonstrated additional impact on morbidity and mortality (progression-free survival and overall survival) but with a transposability of results that is not guaranteed;

- the lack of demonstrated impact on quality of life;
- the absence of any demonstrated additional impact on the organisation of care;
- the lack of any demonstrated additional impact on the care and life pathway;

ENHERTU (trastuzumab deruxtecan) is unlikely to have an additional impact on public health.

Considering all these elements, the Committee deems that the clinical benefit of ENHERTU 100 mg (trastuzumab deruxtecan) powder for concentrate for solution for infusion is substantial in the MA indication.

The Committee issues a favourable opinion for inclusion of ENHERTU 100 mg (trastuzumab deruxtecan) powder for concentrate for solution for infusion in the hospital formulary list of reimbursed proprietary medicinal products approved for use in the MA indication and at the MA dosages.

Clinical Added Value

Considering:

- demonstration in a phase 3, comparative, randomised, open-label study of the superiority of trastuzumab deruxtecan compared to the investigator's choice of chemotherapy (capecitabine, eribuline, gemcitabine, paclitaxel or nab-paclitaxel), for the treatment of adult patients with unresectable or metastatic HER2-low breast cancer who have received prior chemotherapy in the metastatic setting or developed disease recurrence during or within six months of completing adjuvant chemotherapy, in terms of:
- progression-free survival, with a median difference of +4.8 months and an HR = 0.50, CI_{95%} [0.40; 0.63];
- overall survival, with a median difference of +6.6 months and an HR = 0.64, CI_{95%}: [0.49; 0.84]);
- and despite the absence of any formal conclusion that can be drawn based on the quality of life results;
- a safety profile deemed to be acceptable compared to chemotherapy but marked by an excess toxicity having led to more frequent treatment discontinuations in the trastuzumab deruxtecan group, with, in particular, more gastrointestinal (constipation, vomiting) and haematological (anaemia) adverse events, as well as diffuse interstitial lung disease/pneumonitis;
- a concomitant development with TRODELVY (sacituzumab govitecan) and for which no direct comparison was expected on the date of this assessment;

the Committee deems that ENHERTU 100 mg (trastuzumab deruxtecan) powder for concentrate for solution for infusion provides a moderate clinical added value (CAV III) compared to chemotherapy.